LPCN - Bathi sadurunge bunga, pajak, lan amortisasi Lipocine Inc

The automation of laboratory tests is accelerating the drug pipeline for Lipocine Inc. (LPCN), as illustrated by the actual operating profit on the GURU.Markets terminal line chart, where the 0.00 metric reflects current dynamics. The financial foundation relies on licensing payments for the Lip'or-Al platform, while investor confidence is bolstered by experienced management successfully advancing endocrine treatments into final-stage trials.

Lipocine Corp - Bathi operasional EBITDA LPCN (periode 23.11.2025 - 11.11.2026)

Ringkesan rincian data analitis Lipocine (LPCN)

- kuotasi saiki lan rata-rata prakiraan nilai:

Kutipan saham Lipocine Corporation|LPCN - Prakiraan konsensus analis

- statistik kapitalisasi pasar:

Nilai pasar Lipocine|LPCN - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- data kapitalisasi buku:

Rega Buku Saham Lipocine|LPCN - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku lipocine.com|LPCN - Total Aset Perusahaan

- indikator total utang lan likuiditas perusahaan:

- rincian asil keuangan lan kelipatan valuasi:

LPCN - Bathi resik perusahaan|Bathi mangsa ngarep Lipocine Inc.|LPCN - Rasio rega marang bathi|Rega marang bathi mangsa ngarep lipocine.com|LPCN - Pangali PEG|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan Lipocine|LPCN - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben siji saham sajrone 12 wulan pungkasan Lipocine|LPCN - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan lipocine.com|LPCN - Wutah bathi ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Lipocine Inc.

Analisis kabeh metrik perusahaan:Lipocine Corporation (LPCN)

Absolute operating profit measures the actual cash flow from core operations, stripped of the impact of depreciation and taxes, which allows for an assessment of the issuer's internal solvency. By analyzing the current EBITDA, an investor can see the financial foundation of Lipocine Inc. (LPCN), where the stability of this metric confirms the company's ability to develop delivery drugs through targeted licensing without the need for mergers.

Karo sapa Lipocine Inc. saingan